Background: Although colon cancer (CC) with microsatellite instability (MSI) has a more favorable prognosis than microsatellite stable (MSS) CC, the impact varies according to clinicopathological parameters. We studied how MSI status affects prognosis in a trial-based cohort of stage II and III CC patients treated with 5-fluorouracil (5-FU)/leucovorin or FOLFIRI.
predictive markers are urgently needed. MSI, 18q loss of heterozygosity, KRAS, BRAF, and TP53 mutations have been intensively investigated in this context [4, [14] [15] [16] , but most are not incorporated into the treatment guidelines nor have they been confronted in large series to traditional stage II high-risk features [13] or to more recent gene expression-based prognostic signatures [17] .
A putative predictive role of MSI for response to 5-fluorouracil (5-FU)-based adjuvant chemotherapy has been a more contentious issue. Some reports have suggested that disease outcome after chemotherapy does not differ between patients with MSI-H and MSS CC [18] , whereas others showed increased sensitivity to 5-FU for the patients with MSI-H CC [19] . Data from randomized clinical trials of 5-FU-based therapy versus surgery only, however, suggested that patients with MSI-H CC do not benefit from 5-FU-based adjuvant chemotherapy compared with surgery-alone [6] . This was confirmed in a pooled analysis [10] , which added 457 cases to the previously published 570 [6] . In a recent study, however, the survival benefit of stage III MSI-H CC patients was maintained under 5-FU [11] .
An issue remains the impact of MSI on the choice of adjuvant therapy. One trial initially suggested a differential effect of irinotecan-based adjuvant chemotherapy (CALGB 89803) in favor of MSI-H patients [20] , but this became marginal in an updated report [8] .
To clarify these controversies, we studied stage-specific prognostic effects of MSI in the homogeneous PETACC-3 trial colon cancer population treated with 5-FU or FOLFIRI. The key question was whether patients with MSI-H CC maintain their survival benefit under 5-FU treatment, when stratified for stage and treatment. In addition, we investigated how tumor site, BRAF and KRAS status, and high-risk stage II factors modulate the prognostic effect of MSI.
patients and methods

patient characteristics
All eligible patients were randomly assigned to receive 6 months of either 5-FU/leucovorin (LV) alone or with irinotecan [21] . MSI status could be determined for 1254 of the 1564 patients of whom tissue was available for analysis (89%), out of the total trial population of 3278 patients [14] . Earlier reports describe how further molecular parameters ( p53 expression, SMAD4 expression, 18q LOH, BRAF, and KRAS mutation status) were obtained [4, 14, 15] . End points were overall survival (OS), defined as the time from randomization until death, and relapse-free survival (RFS), defined as the time from randomization to local, regional, or distant relapse, the occurrence of a second primary colon cancer or death.
MSI determination
MSI was evaluated at 10 different microsatellite loci containing mono-or dinucleotide repeated sequences. The panel consisted of the five markers from the Bethesda reference panel, with the addition of five markers which were also suggested during the International Workshop on HNPCC in 1997 (BAT-25, BAT-26, D2S123, D5S346, TGFBR2, BAT-40, D17S787, D18S69,  D17S250 , and D18S58) [22] . The amplified PCR products were analyzed using the automated ABI Prism Sequencer Model 3100 Genetic Analyzer (Applied Biosystems, Foster City, USA). A locus was called unstable if unequivocal instabilities were seen in the tumor sample in comparison with the paired normal DNA of the same patient. MSI was graded as high (MSI-H) when three or more markers were unstable, low (MSI-L) when one or two markers were unstable, and stable (MSS) when all markers were stable. For analysis, MSI-L and MSS populations were pooled to MSI-L/S.
The determination of the other markers has been described before [4, 14, 15] .
statistical analyses
Survival curves were determined using Kaplan-Meier methods and compared using the log-rank test. Figure 1A and B). A statistically significant interaction between stage and MSI status was found for OS (P = 0.047), still borderline significant for RFS (P = 0.06).
the prognostic value of MSI is not affected by 5-FU/ LV versus FOLFIRI treatment An interaction test between treatment and MSI status within stage III patients, however, was not significant (P = 0.31 for RFS and P = 0.18 for OS).
When patients were stratified according to MSI status, RFS and OS were similar in both treatment arms. We could not confirm the benefit suggested by Bertagnolli et al. [8] for irinotecan addition in MSI-H tumors (supplementary Table S1 , available at Annals of Oncology online). 
MSI is prognostic in both the right and left colon
Right-sided carcinomas were almost five times more often MSI-H than left-sided carcinomas. More precisely, we found a gradual pattern of MSI-H incidence as reported elsewhere [23] . RFS was better for patients with MSI-H than for MSI-L/S CC, regardless of side. In the right colon, OS was statistically significantly different between MSI-H and MSI-L/S CC, but not in the left. Of note is the similarity of the two HRs ( Figure 2) , with a non-significant interaction. As left CCs are less frequently MSI-H than right CCs (n = 46versus 144), the power of tests in this subgroup is lower. For patients with a stage II carcinoma in the left colon, RFS was similar for MSI-H and MSI-L/S CC, whereas in the right colon, RFS was significantly better for patients with MSI-H CC. For patients with stage II carcinomas in the left colon, MSI status had no effect on OS. There was no event for the 64 MSI-H CC in the right colon. For stage III patients, RFS and OS tended to be better for MSI-H carcinomas, irrespective of site, but this trend was not significant. These observations were confirmed in multivariable models including BRAF mutation status and gender.
MSI status and BRAF/KRAS status
BRAF-mutated CCs were almost four times more often MSI-H than BRAF wild-type CC. In contrast, KRAS-mutated CCs were 1.5 times less often MSI-H than KRAS wild-type CC (Table 1) . In patients with a double wild-type CC, MSI status had no effect on RFS or OS (Figure 2 ). For patients with a KRAS-mutated CC, however, RFS and OS were clearly better. An interaction test for KRAS and MSI status was significant (P = 0.005). For BRAFmutated carcinomas, the CIs were larger, but the effect was still significant for both RFS and OS. A test for interaction between MSI and BRAF status, however, was not significant (P = 0.14). Conversely, BRAF status was not prognostic in patients with a MSI-H CC (RFS: HR = 1.26, 95% CI 0.59-2.70, P = 0.55; OS: HR = 1.53, 95% CI 0.63-3.70, P = 0.35). Similar results were obtained in multivariable analyses when stratified by stage (supplementary Table S2 , available at Annals of Oncology online).
MSI status and stage II risk factors
As shown in supplementary Table S3 , available at Annals of Oncology online, the distribution of MSI-H and MSI-L/S according to stage II risk factors was similar in both groups, except for poorly differentiated CC, which are rare (5.3% of all stage II tumors) but more often MSI-H. Small patient numbers allowed only univariate analyses of these risk factors in the MSI-H group. T stage (HR = 5.28, 95% CI 0.88-31.64, P = 0.07), positive margins (HR = 11.53, 95% CI 1.28-104.15, P = 0.03), and perforation (HR = 8.40, 95% CI 1.40-50.38, P = 0.02) were prognostic but with high uncertainty due to small patient numbers.
When combining risk factors into a high-risk group with at least one risk factor and a low-risk group without any risk factor, the HRs of patients with MSI-L/S CC were higher than those of high-risk patients both in RFS (HR = 3.63, 95% CI 1.46-9.04, P = 0.006 versus HR = 2.40, 95% CI 1.28-4.47, P = 0.006) and OS (HR = 6.03, 95% CI 1.46-24.91, P = 0.01 versus HR = 2.80, 95% CI 1.25-6.28, P = 0.01). This suggests that the prognostic value of MSI status is stronger than that of the combined classical risk factors for stage II patients. In a Figure S1 and Table S4 , available at Annals of Oncology online).
discussion
Our results confirm earlier reports [1, 5-8, 10, 18] that MSI-H colon cancer patients have a better survival than those with MSI-L/S tumors (supplementary Table S5 , available at Annals of Oncology online). Furthermore, we confirm MSI-H tumors to be more often stage II, located in the proximal colon, and of poor or undifferentiated histology, in line with previous reports [8, 10, 11, 24] . We found the MSI-H effect on RFS and OS to be stronger in stage II than in stage III patients [9] . The striking effect in stage II, even though in both arms patients were treated with 5-FU, suggests that patients with MSI-H tumors have a good prognosis, even when treated. Earlier work of Sargent et al. [10] has suggested a lack of benefit from 5-FU-based chemotherapy, but in the absence of an untreated control arm, however, our dataset cannot assess directly the effect of 5-FU on MSI-H patients.
Furthermore, we have shown that MSI-H colon cancer patients treated with FOLFIRI do not fare better than those treated with only 5-FU/LV [12] , in contrast to an earlier report of Bertagnolli et al. [20] . More in line with our data, Bertagnolli et al. [8] recently reported, in a larger patient cohort, an only marginally significant increase in RFS for 5-FU-/irinotecantreated MSI-H patients, when all other risk factors were taken into account. We found no evidence for stage-specific or overall interactions between treatment and MSI status. Nevertheless, in the above-mentioned two trials, different irinotecan-based regimens were used. These differences must be taken into consideration in cross-trial comparisons.
We confirm the high frequency of BRAF mutations in the MSI-H population [25] . As a novel observation, we find MSI to be prognostic in KRAS-and BRAF-mutated, but not in double wild-type, patients. BRAF, however, had no prognostic impact in MSI-H patients, possibly limited by sample size [26] .
A still unanswered question involves the potential impact of the site of the primary tumor, for which we report novel data on the PETACC3 cohort. We found no difference in RFS, between right-and left-sided MSI-H carcinomas. OS of patients with a right-sided MSI-H CC was significantly better compared with those with a right-sided MSI-S/L CC, as previously reported [27] . Our data, however, do not provide convincing evidence in favor of or against a benefit for patients with a left-sided MSI-H CC. In a recent publication, Sinicrope et al. [28] reported that, although patients with a MSI-H right-sided CC have a statistically significant DFS advantage, the outcome of those with a left- [29] . In terms of RFS and OS, MSI-H status was slightly stronger than the combination of high-risk factors. Among high-risk factors, T-stage was the strongest. Comparison between T-stage and MSI status resulted in a similar effect on outcome, as we previously reported [15] . Previously published data from the Sargent group [10, 30] advocated that MSI-H patients might be spared adjuvant treatment. The lack of untreated patients in our study prevents a direct comparison, but we found that stage II patients with T3 and MSI-H CC fare very well. Given the modest treatment effect of 5-FU in this population, they seem to represent the best candidate group for omitting adjuvant treatment. Conversely, patients with MSI-S/ L T4 CC fared much worse, even though they received chemotherapy. For the intermediate-risk patient with a MSI-H T4 or a MSI-S/L T3 CC, other factors need to be considered before a conclusion can be reached.
In conclusion, our results confirm that MSI-H is strongly prognostic for RFS and OS for stage II patients, and less so for stage III patients. In the presence of 5-FU treatment, stage II patients with MSI-H tumors maintain their survival advantage in comparison with MSI-L/S patients and adding irinotecan has no added benefit. Additional parameters (including gene expression profiling, ploidy, methylation, and microRNA expression) have to be explored in order to more accurately define stage II patients who require adjuvant treatment and to predict which patients will respond. Based on new emerging information, further exploratory analyses in large patients' cohorts looking also at the impact of site, mutation profile, and genomic signatures will be necessary to further appreciate the molecular and prognostic impact of MSI status in colon cancer. references
